MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Takeda Pharmaceutical Co Ltd Company Profile (OTCMKTS:TKPYY)

Consensus Ratings for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2014$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014Q4$0.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY)
DateHeadline
06/25/16 10:27 AMTakeda’s norovirus vaccine first to reach human trials
06/21/16 08:00 PMTB Alliance and Takeda Announce Advancement of Joint Program Investigating Promising Compounds for Novel TB Therapies Through Global Health Innovative Technology Fund - [Business Wire] - The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases. In June 2013, TB Alliance and Takeda initiated a program to screen Takeda’s library of 20,000 proprietary compounds to identify potential candidates that showed promise to be further developed into new TB treatments. For Takeda, this program with TB Alliance is an excellent opportunity to leverage, as part of Takeda’s corporate social responsibility program, the company’s drug discovery expertise for communicable diseases, in addition to Takeda’s focus on the oncology, gastroenterology and central nervous system therapeutic areas.
06/16/16 07:00 PMTri-Institutional Therapeutics Discovery Institute expands focus to include antibody drug discovery research
06/16/16 07:00 PMTakeda Pharmaceutical : Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.
06/16/16 05:00 PMTri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd. - [Business Wire] - NEW YORK & OSAKA, Japan--(BUSINESSWIRE)-- Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. (TSE:4502) from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.
06/16/16 11:17 AMResearch report covers the Blood Cancer Treatment Market Growth, 2016-2026
06/16/16 10:45 AMMersana to advance cancer killing drug to clinical trials with $33M investment -
06/16/16 06:30 AM[$$] Mersana Therapeutics Raises $33M Series C, Plans Cancer Clinical Trials -
06/15/16 06:41 PMCelgene joins DNDi's 'Drug Discovery Booster'
06/11/16 12:31 PMEXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care - [PR Newswire] - This data was presented at the American Diabetes Association's 76th Scientific Sessions, and also published in Diabetes Care. "Heart disease, or CV disease, is the leading cause of death in patients with Type 2 diabetes,2 and is responsible for between 50 and 80 percent of deaths in people with diabetes,3 so it's critical we have a clear understanding of the impact these medications have on patients with Type 2 diabetes who are at a high risk for CV diseases such as those involved in EXAMINE," said William B. White, MD, Professor, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, U.S., on behalf of the EXAMINE Steering Committee and Investigators.
06/06/16 08:38 AMTakeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions - [PR Newswire] - OSAKA, Japan, June 6, 2016 /PRNewswire/ -- Takeda Pharmaceuticals Company Limited , ("Takeda") will present eight abstracts at the American Diabetes Association's 76 th Scientific ...
06/03/16 09:50 AMHusband blames pharmaceutical companies for wife's death
06/01/16 09:00 AMTrintellix (vortioxetine) Now Available in U.S. Pharmacies - [PR Newswire] - DEERFIELD, Ill. and OSAKA, Japan, June 1, 2016 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies. Takeda and Lundbeck recently announced that the trade name for the vortioxetine product in the United States would be changed to Trintellix to avoid name confusion. The formulation, indication and dosages of Trintellix remain the same as that of Brintellix, which was originally approved by the U.S. Food and Drug Administration (FDA) in September 2013.
05/26/16 07:56 PMValeant rejected joint takeover bid from Takeda, TPG in spring: WSJ - (Reuters) - Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP [TPG.UL] this spring that the Canadian...
03/15/16 07:58 AMUPDATE 1-Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant - March 15 (Reuters) - Orexigen Therapeutics Inc said it agreed to buy the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co Ltd and will tap Canada's Valeant...
02/09/16 12:10 PMTakeda Pharmaceutical Co., Ltd. Earnings Analysis: Q3, 2016 By the Numbers -
02/08/16 03:10 PMMersana plans human trials of first cancer drug by this summer -
02/03/16 07:35 PMFDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) - [PR Newswire] - OSAKA, Japan and VALBY, Denmark, Feb. 3, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD). Earlier today, the committee also discussed that cognitive dysfunction in MDD represents an appropriate drug development target.
02/03/16 02:07 PMTakeda Pharmaceutical Co., Ltd. – Value Analysis (US OTC:TKPYY) : February 3, 2016 -
02/02/16 10:38 PMTakeda Assembles Team to Evaluate Zika Vaccine Possibilities -
01/27/16 11:01 AM12:01 pm Takeda Pharma confirms FDA approval of Dexilant SoluTab delayed-release orally disintegrating tablets -
01/27/16 10:59 AMFDA Approves Takeda's Dexilant SoluTab (dexlansoprazole) - [PR Newswire] - DEERFIELD, Ill., Jan. 27, 2016 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., (Takeda) (TSE: 4502) today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor (PPI) indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in adults 18 years and older.
01/25/16 10:45 AMGlaxo evaluating possibility of using vaccine technology for Zika - [Reuters] - GlaxoSmithKline Plc is concluding feasibility studies evaluating whether its vaccine technology is suitable for the Zika virus, which has been linked to brain damage in thousands of babies in Brazil, a spokeswoman told Reuters. Zika will likely spread to all countries in the Americas except for Canada and Chile, the World Health Organization said on Monday.
01/13/16 03:00 PMAsia's Biggest Drugmaker Eyes Greener Shores as Fortunes Fade at Home -
01/12/16 07:47 AMThis 230-year-old Japanese drugmaker wants to turn into 'a 33,000-person startup' -
01/05/16 05:00 PMTakeda Acquires U.S. Biologics Manufacturing Facility - [Business Wire] - OSAKA, Japan--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., ...
12/28/15 03:45 PMTakeda, Teva Reveal Outlook of Japanese Business Venture -
12/28/15 08:55 AMTeva Pharmaceutical: Joint Venture With Takeda Will Be 'Instantly Accretive' To 2016 EPS And Beyond -
12/27/15 08:55 PMCORRECTING and REPLACING Takeda Provides Further Information about Its New Business Venture with Teva - [Business Wire] - OSAKA, Japan & JERUSALEM--(BUSINESSWIRE)-- Insert after fifth paragraph, first sentence of release: The new business venture will be instantly accretive to Teva's non GAAP EPS in 2016 and beyond. Takeda Pharmaceutical Company Limited (TOKYO:4502) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - News) (TASE:TEVA.TA - News) today made the below follow-up announcement regarding the overview of their new business venture in Japan, which was initially disclosed on November 30, 2015 in the press release titled, "Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan". The new business venture, to be established in or after April 2016, will deliver Teva's high-quality generic medicines and some of Takeda's long listed products to patients and healthcare professionals in Japan, leveraging Takeda's corporate brand and unique distribution network in Japan and Teva's wide product portfolio and cutting-edge business efficiency.
12/27/15 07:44 PMINSERTING and REPLACING Takeda Provides Further Information about its New Business Venture with Teva - [Business Wire] - OSAKA, Japan & Jerusalem--(BUSINESSWIRE)-- Insert after 1st sentence in last bullet of release: The new business venture will be instantly accretive to Teva's non GAAP EPS in 2016 and beyond. The corrected ...
12/16/15 04:39 AMAstraZeneca to buy Takeda's lung business for £383m -
About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TKPYY
  • CUSIP:
Key Metrics:
  • Previous Close: $21.35
  • 50 Day Moving Average: $21.47
  • 200 Day Moving Average: $23.39
  • P/E Ratio: 44.37
  • P/E Growth: 0.00
  • Market Cap: $33.56B
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha